The place of sulfonylureas in the therapy for type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 55, Issue SUPPL. 1, 2006, Pages

  Del Prato, Stefano ^a   Pulizzi, Nicolò ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLYPROTHIAZOL; INSULIN; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE;

APOPTOSIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM; GENETIC HETEROGENEITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPEREMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; TISSUE SPECIFICITY; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; PRACTICE GUIDELINES; SULFONYLUREA COMPOUNDS; WEIGHT GAIN;

EID: 33646053813     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.02.003     Document Type: Article

References (60)

1. International Diabetes Federation. Facts and figures. Available at: (2004). http://www.idf.org/home/ [Accessed December 20, 2005]
2. Gonzalez-Clemente J.M., Galdon G., Mitjavila J., Minarro A., Gimenez-Perez G., and Mauricio D. Translation of the recommendations for the diagnosis of diabetes mellitus into daily clinical practice in a primary health care setting. Diabetes Res Clin Pract 62 (2003) 123-129
3. Turner R.C., and Holman R.R. Lessons from UK Prospective Diabetes Study. Diabetes Res Clin Pract 28 (1995) S151-S157
4. Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia 45 (2002) S5-S12
5. Gilmer T.P., O'Connor P.J., Manning W.G., and Rush W.A. The cost to health plans of poor glycemic control. Diabetes Care 20 (1997) 1847-1853
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
7. International Diabetes Federation. Global guidelines for type 2 diabetes. Available at. http://www.idf.org/home/ [Accessed December 20, 2005]
8. Saydah S.H., Fradkin J., and Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291 (2004) 335-342
9. Liebl A., Mata M., and Eschwege E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 45 (2002) S23-S28
10. DeFronzo R.A. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 88 (2004) 787-835
11. Bagust A., and Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. Q J Med 96 (2003) 281-288
12. UKPDS Study Group. Overview of six years' therapy of type 2 diabetes-a progressive disease. Diabetes 44 (1995) 1249-1258
13. Del Prato S., Felton A.M., Munro N., Nesto R., Zimmet P., and Zinman B. Global Partnership for Effective Diabetes Management. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract 59 (2005) 1345-1355
14. Del Prato S., Marchetti P., and Bonadonna R.C. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 51 Suppl 1 (2002) S109-S116
15. Gastaldelli A., Ferrannini E., Miyazaki Y., Matsuda M., and DeFronzo R.A. San Antonio metabolism study. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47 (2004) 31-39
16. Weyer C., Bogardus C., Mott D.M., and Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104 (1999) 787-794
17. Weyer C., Tataranni P.A., Bogardus C., and Pratley R.E. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 24 (2001) 89-94
18. European Diabetes Policy Group. A desktop guide to type 2 diabetes. Diabet Med 16 (1999) 716-730
19. Management of type 2 diabetes-management of blood glucose-NICE summary. Available at. http://www.nelh.nhs.uk/guidelinesdb/html/fulltext-guidelines/Bloodglucose.html
20. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 27 Suppl 1 (2004) S15-S34
21. Jennings A.M., Wilson R.M., and Ward J.D. Symptomatic hypoglycaemia in NIDDM patients treated with oral hypoglycaemiac agents. Diabetes Care 12 (1989) 203-208
22. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
23. Ferner R.E., and Neil H.A. Sulphonylureas and hypoglycemia. BMJ 296 (1988) 949-950
24. Shorr R.I., Ray W.A., Daugherty J.R., and Griffin M.R. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 44 (1996) 751-755
25. Asplund K., Wiholm B.-E., and Lithner F. Glibenclamide-associated hypoglycemia: a report on 57 cases. Diabetologia 24 (1983) 412-417
26. Van Staa T., Abenhaim L., and Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 50 (1997) 735-741
27. Ben-Ami H., Nagachandran P., Mendelson A., and Edoute Y. Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med 159 (1999) 281-284
28. Draeger K.E., Wernicke-Panten T., Lomp H.J., Schuler E., and Rosskamp R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 28 (1996) 419-425
29. Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 34 (2004) 535-542
30. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 128 (1998) 165-175
31. Luis Bautista J., Bugos C., Dimberger G., and Atherton T. Efficacy and safety profile of glimepiride in Mexican American patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 25 (2003) 194-209
32. Martin S., Kolb H., Beuth J., van Leendert R., Schneider B., and Scherbaum W.A. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in type 2 diabetes: a multicentre retrospective cohort study. Diabetologia 46 (2003) 1611-1617
33. Bugos C., Austin M., Atherton T., and Viereck C. Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis. Diabetes Res Clin Pract 50 Suppl 1 (2000) S47 [Abstract P251]
34. Simonson D.C., Kourides I.A., Feinglos M., Shamoon H., Fischette C.T., and Glipizide Gastrointestinal Therapeutic System Study Group. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicentre, randomized, placebo-controlled clinical trials. Diabetes Care 20 (1997) 597-606
35. 2+ concentration. J Biol Chem 273 (1998) 33501-33507
36. Maedler K., Carr R.D., Bosco D., Zuellig R.A., Berney T., and Donath M.Y. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90 (2005) 501-506
37. Del Guerra S., Marselli L., Lupi R., Boggi U., Mosca F., Benzi L., et al. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications 19 (2005) 60-64
38. Poitout V., and Robertson R.P. Minireview: secondary beta-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Endocrinology 143 (2002) 339-342
39. Del Prato S., Lupi R., Bugliani M., Del Guerra S., Torri S., Sbrana S., et al. Glucotoxicity in human pancreatic islets is mediated by oxidative stress: evidence for limited defense capacity. Diabetologia 47 Suppl 1 (2004) A39
40. McGavin J.K., Perry C.M., and Goa K.L. Gliclazide modified release. Drugs 62 (2002) 1357-1364
41. Kimoto K., Suzuki K., Kizaki T., Hitomi Y., Ishida H., Kastuta H., et al. Gliclazide protects pancreatic beta-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun 303 (2003) 112-119
42. Grupillo M., Del Guerra S., Masini M., Lupi R., Bugliani M., Torri S., et al. Gliclazide protects isolated human islets from apoptosis induced by intermittent high glucose: the role of oxidative stress. Diabetologia 48 Suppl 1 (2005) A45
43. Lebovitz H.E., and Melander A. Sulfonylureas: basic aspects and clinical uses. In: Alberti K.G.M.M., Zimmet P., DeFronzo R.A., and Keen H. (Eds). International textbook of diabetes mellitus. 2nd ed. (1997), Wiley & Sons Ltd, London 817-840
44. +-channels. Annu Rev Pharmacol Toxicol 33 (1993) 597-637
45. Lazdunski M. Ion channel effects of antidiabetic sulfonylureas. Horm Metab Res 28 (1996) 488-495
46. Geisen K., Vegh A., Krause E., and Papp J.G. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res 28 (1996) 496-507
47. Mocanu M.M., Maddock H.L., Baxter G.F., Lawrence C.L., Standen N.B., and Yellon D.M. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 103 (2001) 3111-3116
48. Maddock H.L., Siedlecka S.M., and Yellon D.M. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 18 (2004) 113-119
49. Scognamiglio R., Avogaro A., Vigili de Kreutzenberg S., Negut C., Palisi M., Bagolin E., et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 51 (2002) 808-812
50. Lee T.M., and Chou T.F. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 88 (2003) 531-537
51. Klepzig H., Kober G., Matter C., Luus H., Schneider H., Boedeker K.H., et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 20 (1999) 439-446
52. Wascher T.C., and Boes U. Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients. Clin Physiol Funct Imaging 25 (2005) 40-46
53. Renier G., Mamputu J.C., and Serri O. Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells. Metabolism 52 8 Suppl 1 (2003) 13-18
54. Jennings P.E. Vascular benefits of gliclazide beyond glycemic control. Metabolism 49 Suppl 2 (2000) 17-20
55. O'Brien R.C., Luo M., Balazs N., and Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 14 (2000) 201-206
56. ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease-pretarax and Diamicron MR controlled evaluation. Diabetologia 9 (2001) 1118-1120
57. DeFronzo R.A., and Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333 (1995) 541-549
58. UKPDS Study Group. A randomised trial of efficacy of early addition of metformin in sulphonylurea-treated non-insulin dependent diabetes. Diabetes Care 21 (1998) 87-92
59. Ahren B., and Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 36 (2004) 867-876
60. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635